EGFR and non-small cell lung carcinoma: The phase II HERTHENA-Lung01 trial evaluated HER3-DXd in 225 patients with advanced EGFR-mutated NSCLC previously treated with EGFR TKI therapy and platinum-based chemotherapy (PBC).